Data from the ongoing study indicate that the combination regimen, known as VELSAM, was well tolerated at doses studied to date and demonstrated anti-tumor activity, with 50% of patients experiencing a response or achieving stable disease. The results were presented at the Congress of European Hematology.
“As we gain additional experience with patients receiving multiple cycles of treatment, we continue to be impressed not only by the responses observed in this heavily pretreated population of patients but also by the patient friendly nature of this treatment regimen,” said principal investigator Dr James Berenson, medical and scientific director of the Institute for Myeloma & Bone Cancer Research in West Hollywood, California.